Abstract
This randomized clinical trial compares the effects of the dipeptidyl peptidase 4 inhibitor linagliptin vs placebo plus usual care on cardiovascular (CV) and renal outcomes in adults with type 2 diabetes and high CV and renal risk.
- Title
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
- Creators - without role
- Julio Rosenstock - The University of Texas Southwestern Medical CenterVlado Perkovic - The George Institute for Global HealthOdd Erik Johansen - Boehringer Ingelheim (Norway)Mark E. Cooper - Monash UniversitySteven E. Kahn - VA Puget Sound Health Care SystemNikolaus Marx - Universitätsklinikum AachenJohn H. Alexander - Clinical Research InstituteMichael Pencina - Clinical Research InstituteRobert D. Toto - The University of Texas Southwestern Medical CenterChristoph Wanner - University of WürzburgBernard Zinman - Mount Sinai HospitalHans Juergen Woerle - Universität UlmDavid Baanstra - Boehringer Ingelheim (Netherlands)Egon Pfarr - Boehringer Ingelheim (Germany)Sven Schnaidt - Boehringer Ingelheim (Germany)Thomas Meinicke - Boehringer Ingelheim (Germany)Jyothis T. George - Boehringer Ingelheim (Germany)Maximilian von Eynatten - Boehringer Ingelheim (Germany)Darren K. McGuire - The University of Texas Southwestern Medical Centerfor the CARMELINA InvestigatorsChin Wei Cheah - SCI,MATH & Technology
- Publication Details
- JAMA : the journal of the American Medical Association, Vol.321(1), pp.69-79
- Publisher
- American Medical Association
- Number of pages
- 11
- Grant note
- Boehringer Ingelheim Eli Lilly
- Identifiers
- 9911359109846
- Academic Unit
- SCI,MATH & Technology
- Language
- English
- Resource Type
- Journal article